Compositions and Methods for Genetically Modifying CD70
AssigneeIntellia Therapeutics, Inc.
InventorsMichael Lam, Ishina Balwani, Ruan Oliveira, Biao Liu, Özgün Kiliç, Boning Zhang
Life of this patent
Estimating the term…
Abstract
Compositions and methods for editing, e.g., altering a DNA sequence, within a CD70 gene are provided. Compositions and methods for reducing or eliminating CD70 protein expression in a cell are provided. Compositions and methods for immunotherapy are provided.
Claims74
An engineered cell, comprising a genetic modification within genomic coordinates chr19:6586002-6591015.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A composition comprising a guide RNA or comprising a guide RNA and an RNA-guided DNA binding agent or a nucleic acid encoding an RNA-guided DNA binding agent, wherein the guide RNA comprises:
- (1)
- a) guide sequence selected from SEQ ID NOs:
- 1-38;
- b) a guide sequence that is at least 20, 21, 22, 23, 24, or 25 contiguous nucleotides of a sequence selected from SEQ ID NOs:
- 1-38;
- c) a guide sequence that is at least 85%, 90%, or 95% identical to a sequence selected from SEQ ID NOs:
- 1-38;
- d) a sequence that comprises 10 contiguous nucleotides ±10 nucleotides of a genomic coordinate listed in Table 2A;
- e) at least 20, 21, 22, 23, or 24, contiguous nucleotides of a sequence from (1)d);
- or
- f) a guide sequence that is at least 85%, 90%, or 95% identical to a sequence selected from (1)d);
- or
- (2)
- a) a guide sequence selected from SEQ ID NOs:
- 101-169;
- b) a guide sequence that is at least 17, 18, 19, or 20 contiguous nucleotides of a sequence selected from SEQ ID NOs:
- 101-169;
- c) a guide sequence that is at least 85%, 90%, or 95% identical to a sequence selected from SEQ ID NOs:
- 101-169;
- d) a sequence that comprises 10 contiguous nucleotides ±10 nucleotides of a genomic coordinate listed in Table 3A;
- e) at least 17, 18, 19, or 20 contiguous nucleotides of a sequence from (2)d);
- or
- f) a guide sequence that is at least 85%, 90%, or 95% identical to a sequence selected from (2)d).
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
An engineered human cell comprising a genetic modification in the HLA-A gene within the genomic coordinates chr6:29942891-29942915, a genetic modification in the HLA-B gene within the genomic coordinates chr6:31355222-31355246, a genetic modification in the CIITA gene within the genomic coordinates chr16:10906643-10906667, a genetic modification in the TGFBR2 gene within the genomic coordinates chr3:30674205-30674229, a genetic modification in the TRAC gene within the genomic coordinates chr14:22547524-22547544, and a genetic modification in the CD70 gene within the genomic coordinates chr19:6590121-6590145.
(canceled)
(canceled)
Dependencies are inferred from the claim text.